Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Neoadjuvant Bevacizumab Plus DOF Versus DOF in Local Advanced Gastric Carcinoma and Its Association With Circulating Tumor Cell

NCT02048540 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT02048540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02048540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Neoadjuvant Bevacizumab Plus DOF Versus DOF in Local Advanced Gastric Carcinoma and Its Association With Circulating Tumor Cell
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2009
Completion date
December 31, 2013
Enrollment
86 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced gastric carcinoma